AYTU BioPharma, Inc. Common Stock (AYTU)

Price$2.25

Value ScoreA

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-10.21%

Price vs S&P 500 (4W)-17.46%

VGM Score56.53

Market Capitalization$24.15M

All Metrics

Book Value / Share (Quarterly)$3.27

P/TBV (Annual)2.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-11.79%

Cash Flow / Share (Quarterly)$-0.13

Price vs S&P 500 (YTD)-29.30%

Gross Margin (TTM)64.78%

Net Profit Margin (TTM)-60.17%

EPS (TTM)$-4.41

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-4.41

Revenue Growth (5Y)19.19%

EPS (Annual)$-2.16

ROI (Annual)-33.26%

Gross Margin (Annual)69.04%

Net Profit Margin (5Y Avg)-51.46%

Cash / Share (Quarterly)$2.49

Revenue Growth QoQ (YoY)-32.74%

ROA (Last FY)-10.92%

Revenue Growth TTM (YoY)-18.24%

EBITD / Share (TTM)$-1.07

ROE (5Y Avg)-90.09%

Operating Margin (TTM)-26.79%

Cash Flow / Share (Annual)$-0.58

P/B Ratio0.69x

P/B Ratio (Quarterly)0.83x

Net Income / Employee (Annual)$-165,400

EV / Revenue (TTM)0.34x

Net Interest Coverage (TTM)-1.32x

ROA (TTM)-28.21%

EV / EBITDA (TTM)5.23x

EPS Incl Extra (Annual)$-2.16

Current Ratio (Annual)1.26x

Quick Ratio (Quarterly)0.85x

3-Month Avg Trading Volume0.05M

52-Week Price Return33.64%

Revenue / Employee (TTM)$690,200

Tangible BV / Share (Quarterly)$16.13

P/S Ratio (Annual)0.36x

Asset Turnover (Annual)0.53x

52-Week High$3.06

Operating Margin (5Y Avg)-47.18%

EPS Excl Extra (Annual)$-2.16

26-Week Price Return1.18%

Quick Ratio (Annual)0.98x

13-Week Price Return-18.43%

Total Debt / Equity (Annual)1.15x

Current Ratio (Quarterly)1.12x

Enterprise Value$19.25M

Revenue / Share Growth (5Y)-40.18%

Asset Turnover (TTM)0.47x

Book Value / Share Growth (5Y)-57.82%

Revenue / Employee (Annual)$809,500

Inventory Turnover (Annual)1.71x

Pretax Margin (Annual)-20.71%

Cash / Share (Annual)$3.45

3-Month Return Std Dev37.10%

Gross Margin (5Y Avg)58.04%

Net Income / Employee (TTM)$-415,300

ROE (Last FY)-71.51%

Net Interest Coverage (Annual)-0.62x

EPS Basic Excl Extra (Annual)$-2.16

P/FCF (TTM)3.66x

Receivables Turnover (TTM)1.88x

Total Debt / Equity (Quarterly)0.62x

EPS Incl Extra (TTM)$-4.41

Receivables Turnover (Annual)2.42x

ROI (TTM)-74.35%

P/S Ratio (TTM)0.43x

Pretax Margin (5Y Avg)-50.09%

Revenue / Share (Annual)$10.57

Tangible BV / Share (Annual)$37.21

Price vs S&P 500 (52W)6.59%

Year-to-Date Return-18.28%

5-Day Price Return-7.21%

EPS Normalized (Annual)$-2.16

ROA (5Y Avg)-27.58%

Net Profit Margin (Annual)-20.43%

Month-to-Date Return-7.21%

Cash Flow / Share (TTM)$-3.85

EBITD / Share (Annual)$-0.66

Operating Margin (Annual)-11.79%

LT Debt / Equity (Annual)0.57x

P/CF (TTM)14.39x

ROI (5Y Avg)-61.20%

LT Debt / Equity (Quarterly)0.27x

EPS Basic Excl Extra (TTM)$-4.41

P/TBV (Quarterly)1.67x

P/B Ratio (Annual)1.03x

Inventory Turnover (TTM)2.15x

Pretax Margin (TTM)-59.49%

Book Value / Share (Annual)$2.11

Price vs S&P 500 (13W)-28.94%

Beta0.24x

Revenue / Share (TTM)$5.38

ROE (TTM)-148.91%

52-Week Low$1.46

vGradeA

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q3 26-0.53est. -0.52

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
AYTUAYTU BioPharma, Inc. Common Stock	A	D	C	$2.25
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products, focusing on pediatric conditions including ADHD. The company is building a clinical pipeline that includes a prospective treatment for vascular Ehlers-Danlos Syndrome, a rare genetic disorder associated with significant morbidity.